Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript
Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call Transcript
Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Eisai Co., Ltd. (ESAIY) Q2 2026 Earnings Call Transcript
Merck, Eisai discontinue late-stage study for liver cancer therapy
Merck-Eisai's cancer drug combo meets one main goal in late-stage study
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
Eisai Co., Ltd. (ESAIY) Discusses On Latest Data On Lemborexant And Novel Orexin Receptor Agonist E2086 At The World Sleep 2025 Transcript
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug
Eisai Co., Ltd. (ESALF) Q1 2026 Earnings Call Transcript
Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds
Eisai Co., Ltd. (ESALF) Q4 2025 Earnings Call Transcript
EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease
EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug
Eisai Co., Ltd. (ESALF) Q3 2024 Earnings Call Transcript
Europe to review safety data for Eisai-Biogen Alzheimer's drug
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen
Eisai: Still Relatively Modest Market-Implied Expectations For Leqembi
Eisai Co., Ltd. (ESALF) Q2 2025 Earnings Call Transcript
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
Eisai will request reconsideration of initial decision for lecanemab in Australia
UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug
Eisai Co Ltd (ESALF) Q1 2025 Earnings Call Transcript
Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
Shares of Japan's Eisai tumble after EU rejects Alzheimer's drug
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
EU medicines regulator rejects Eisai-Biogen Alzheimer's drug
The 3 Best Neuroscience Biotech Stocks to Buy Now
Eisai: Margin Of Safety From Very Modest Penetration Expectations
Lilly follows Biogen-Eisai in securing US FDA approval for Alzheimer's drug
Japan's Eisai developing dementia drug for US market, Nikkei reports
Eisai and Biogen launch Alzheimer's drug Leqembi in China
FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
Eisai Co Ltd. (ESALF) Q4 2024 Earnings Call Transcript